<?xml version="1.0" encoding="UTF-8"?>
<p>MR offers a chance to prioritize drug targets using human evidence early in the drug development pipeline. We can also explore repurposing opportunities for already-licenced drugs, which have passed safety assessment and could reach patients sooner and at a lower cost (
 <xref rid="fcaa031-B28" ref-type="bibr">Evans and Davey Smith, 2015</xref>). MR has already been applied in drug development for neurodegenerative disease, and below we discuss several promising examples.
</p>
